Agenus Stock

Agenus Dividend 2024

Agenus Dividend

0 USD

Agenus Dividend yield

Ticker

AGEN

ISIN

US00847G7051

WKN

A1JLKZ

How much dividend does Agenus 2024 pay?

According to the latest status from October 2024, Agenus paid a total of 0 USD per share in dividends within the last 12 months. With the current Agenus price of 4.87 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Agenus Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Agenus Dividend Safe?

Agenus has been increasing the dividend for 0 years.

Over the past 10 years, Agenus has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Agenus's Dividend Distributions

Agenus’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Agenus's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Agenus's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Agenus’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Agenus Aktienanalyse

What does Agenus do?

Agenus Inc is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus started as a small start-up company focusing on the research of antibodies against chronic viral diseases. In 2000, the company developed the first approved therapeutic vaccine against cervical cancer in collaboration with GlaxoSmithKline. Since then, Agenus has expanded its business to the discovery, development, and commercialization of novel antibody and immunotherapies. The company has brought many groundbreaking medications to the market, including a cancer immunotherapy called Prophage, which is approved for the treatment of glioblastoma, an aggressive brain tumor. Agenus' business model focuses on the development of immunotherapies that utilize the body's immune system to fight against cancer or other diseases. The company's research and development programs are divided into three areas: antibody development, immunotherapy, and preclinical developments. Agenus has a comprehensive library of antibodies and utilizes them to develop new and innovative antibodies and antibody conjugates that can be used to treat cancer and autoimmune diseases. The company has also developed a range of immunotherapies aimed at supporting the body's immune system in fighting against cancer and other diseases, including therapies targeting checkpoint inhibitors that enhance the body's immune response to cancer cells. In addition, Agenus has a broad portfolio of preclinical programs aimed at developing new drugs and therapies for the treatment of cancer and other diseases. Agenus has introduced a range of products to the market that can be used for the treatment of cancer and other diseases, including Prophage, a personalized cancer vaccine tailored to each patient for the treatment of glioblastoma. Other products include Zalifrelimab, a checkpoint inhibitor that aims to enhance the body's immune response to cancer, INCAGN2385, another checkpoint inhibitor that enhances T-cell activity in the body, and INCAGN1949, an antibody therapy targeting the GITR protein that can help enhance the immune response against cancer cells. In summary, Agenus is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company has a long history in antibody research and development and has expanded its efforts to develop immunotherapies. Agenus has a comprehensive library of antibodies and has introduced a range of products to the market for the treatment of cancer and other diseases. With a broad portfolio of products and preclinical programs, Agenus remains a key player in the field of immunotherapies and is expected to drive further groundbreaking developments in the future. Agenus is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Agenus stock

How much dividend does Agenus pay?

Over the past 12 months, Agenus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agenus is expected to pay a dividend of 0 USD.

What is the dividend yield of Agenus?

The current dividend yield of Agenus is .

When does Agenus pay dividends?

Agenus pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agenus?

Agenus paid dividends every year for the past 0 years.

What is the dividend of Agenus?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agenus located?

Agenus is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agenus kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agenus from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Agenus pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Agenus in the year 2023?

In the year 2023, Agenus distributed 0 USD as dividends.

In which currency does Agenus pay out the dividend?

The dividends of Agenus are distributed in USD.

Andere Kennzahlen von Agenus

Our stock analysis for Agenus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agenus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.